Business Of Biotech

Matt Pillar
  • 4,7 (81)
  • МЕНЕДЖМЕНТ
  • ЕЖЕНЕДЕЛЬНО
Business Of Biotech

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Bioprocess Online and Life Science Connect and brought to you by Cytiva.

  1. -2 ДН.

    Serving The Underserved With Gates MRI's Claire Wagner, M.D.

    We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there. She shares the development of her North Star while working with the incomparable Dr. Paul Farmer in Rwanda, and how that experience translates to the growth of a biopharmaceutical company taking big swings for grossly un...

    47 мин.

  2. 4 НОЯБ.

    An Unanticipated Biotech Startup With OS Therapies' Paul Romness

    We love to hear from our listeners. Send us a message. Becoming a biotech CEO wasn't on Paul Romness' bingo card. He'd forged his place in the biopharma industry as a foremost public and policy affairs expert. Thirteen years at J&J, more than 5 at Amgen, and half a dozen at Boehringer Ingelheim had earned him the right to coast into a consulting gig that would enable him to finish out his career on his terms. Then his daughter's best friend Olivia, a teenage girl and neighbor he'd wa...

    49 мин.

  3. 28 ОКТ.

    Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright

    We love to hear from our listeners. Send us a message. It might just be coincidence, but it sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'l...

    44 мин.

  4. 21 ОКТ.

    Obesity Tx End-Around With Skye Bioscience's Punit Dhillon

    We love to hear from our listeners. Send us a message. While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant last month, Skye Bioscience Chairman and CEO Punit Dhillon is shaking it off. He's confident that his company's antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On this episode o...

    1 ч. 3 мин.

  5. 14 ОКТ.

    Biotech C-Suite Construction With Allan Shaw

    We love to hear from our listeners. Send us a message. Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. We cover strategies for the step-wise assembly of effective executive teams, the importance of aligning key hires with clinical and regulatory milestones, managing salaries in line with cash runways, the pros and cons of fractional/consultative leadership, when it's time to turn fractional into full-time, and a whole-lot more. If you're growi...

    52 мин.

  6. 7 ОКТ.

    The Peptide Promise With NervGen's Mike Kelly

    We love to hear from our listeners. Send us a message. Mike Kelly faced a self-reckoning before he took the job as CEO at NervGen, a company developing peptide therapeutics targeted specifically at central nervous system repair. The veteran of life sciences business development knew the ropes of the biotech C-suite. He’d been a CEO twice before. He knew how to launch drugs, having seen commercial success several times before. He even knew how to sell them—he’d started his career carrying the ...

    59 мин.

  7. 30 СЕНТ.

    Biotech Course Correction With Treehill Partners' Ali Pashazadeh

    We love to hear from our listeners. Send us a message. It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite frequently, and on this episode of the Business of Biotech podcast, he offers a fantastic reason why. Yes, it's a bit of a departure from our normal routine of biotech founders occupying the guest chair. But, Pashazadeh's no-holds-barred reflections...

    1 ч. 17 мин.

  8. 23 СЕНТ.

    An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D.

    We love to hear from our listeners. Send us a message. Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly as it relates to using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. Today, she's Chief Business Officer at ProFluent Bio, a company that's committed to democratizing access to open-source AI gene editing tools that are custom-built for pharmaceuti...

    1 ч. 14 мин.
См. все (228)

4,7
из 5
Оценок: 81

Об этом подкасте

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Bioprocess Online and Life Science Connect and brought to you by Cytiva.

Информация

  • Автор
    Matt Pillar
  • Годы выхода
    2020 - 2024
  • Выпуски
    228
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2024 Business Of Biotech
  • Сайт подкаста
    Business Of Biotech

Вам может также понравиться

Чтобы прослушивать выпуски с ненормативным контентом, войдите в систему.

Следите за новостями подкаста

Войдите в систему или зарегистрируйтесь, чтобы следить за подкастами, сохранять выпуски и получать последние обновления.
Выберите страну или регион

Африка, Ближний Восток и Индия

Азиатско-Тихоокеанский регион

Европа

Латинская Америка и страны Карибского бассейна

США и Канада